144 related articles for article (PubMed ID: 22088139)
21. Compatibility of chewing gum excipients with the amino acid L-cysteine and stability of the active substance in directly compressed chewing gum formulation.
Kartal A; Björkqvist M; Lehto VP; Juppo AM; Marvola M; Sivén M
J Pharm Pharmacol; 2008 Sep; 60(9):1131-8. PubMed ID: 18718115
[TBL] [Abstract][Full Text] [Related]
22. Salt-assisted liquid-liquid microextraction with water-miscible organic solvents for the determination of carbonyl compounds by high-performance liquid chromatography.
Gupta M; Jain A; Verma KK
Talanta; 2009 Dec; 80(2):526-31. PubMed ID: 19836515
[TBL] [Abstract][Full Text] [Related]
23. Characterization of degradation products of amorphous and polymorphic forms of clopidogrel bisulphate under solid state stress conditions.
Raijada DK; Prasad B; Paudel A; Shah RP; Singh S
J Pharm Biomed Anal; 2010 Jul; 52(3):332-44. PubMed ID: 19520540
[TBL] [Abstract][Full Text] [Related]
24. Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book database.
Paulekuhn GS; Dressman JB; Saal C
J Med Chem; 2007 Dec; 50(26):6665-72. PubMed ID: 18052022
[TBL] [Abstract][Full Text] [Related]
25. Implementing quality by design in pharmaceutical salt selection: a modeling approach to understanding disproportionation.
Merritt JM; Viswanath SK; Stephenson GA
Pharm Res; 2013 Jan; 30(1):203-17. PubMed ID: 22918819
[TBL] [Abstract][Full Text] [Related]
26. A validated stability indicating ion-pair RP-LC method for zoledronic acid.
Rao BM; Srinivasu MK; Rani ChP; kumar SS; Kumar PR; Chandrasekhar KB; Veerender M
J Pharm Biomed Anal; 2005 Sep; 39(3-4):781-90. PubMed ID: 15922532
[TBL] [Abstract][Full Text] [Related]
27. Stress degradation studies on lornoxicam using LC, LC-MS/TOF and LC-MSn.
Modhave DT; Handa T; Shah RP; Singh S
J Pharm Biomed Anal; 2011 Nov; 56(3):538-45. PubMed ID: 21757313
[TBL] [Abstract][Full Text] [Related]
28. LC and LC-MS study of stress decomposition behaviour of isoniazid and establishment of validated stability-indicating assay method.
Bhutani H; Singh S; Vir S; Bhutani KK; Kumar R; Chakraborti AK; Jindal KC
J Pharm Biomed Anal; 2007 Mar; 43(4):1213-20. PubMed ID: 17118610
[TBL] [Abstract][Full Text] [Related]
29. A high-temperature liquid chromatographic reactor approach for investigating the solvolytic stability of a pharmaceutical compound and an investigation of its retention behavior on a C18-modified zirconia stationary phase.
Skrdla PJ; Bopra A; Chasse T; Wang T
J Pharm Biomed Anal; 2008 Jun; 47(2):312-9. PubMed ID: 18295428
[TBL] [Abstract][Full Text] [Related]
30. A validated stability-indicating LC method for acetazolamide in the presence of degradation products and its process-related impurities.
Srinivasu P; Subbarao DV; Vegesna RV; Sudhakar Babu K
J Pharm Biomed Anal; 2010 May; 52(1):142-8. PubMed ID: 20053517
[TBL] [Abstract][Full Text] [Related]
31. Salt disproportionation: A material science perspective.
Thakral NK; Kelly RC
Int J Pharm; 2017 Mar; 520(1-2):228-240. PubMed ID: 28163222
[TBL] [Abstract][Full Text] [Related]
32. Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy.
Verbeeck RK; Kanfer I; Walker RB
Eur J Pharm Sci; 2006 May; 28(1-2):1-6. PubMed ID: 16413762
[TBL] [Abstract][Full Text] [Related]
33. X-ray powder diffractometry of intact film coated tablets--an approach to monitor the physical form of the active pharmaceutical ingredient during processing and storage.
Yamada H; Suryanarayanan R
J Pharm Sci; 2007 Aug; 96(8):2029-36. PubMed ID: 17541977
[TBL] [Abstract][Full Text] [Related]
34. LC-MS characterization of trace impurities contained in calcium folinate.
Francese G; Corana F; Meneghetti O; Marazza F
J Pharm Biomed Anal; 2005 Sep; 39(3-4):757-63. PubMed ID: 15927438
[TBL] [Abstract][Full Text] [Related]
35. Understanding drug-excipient compatibility: oxidation of compound A in a solid dosage form.
Wu Y; Dali M; Gupta A; Raghavan K
Pharm Dev Technol; 2009; 14(5):556-64. PubMed ID: 19743950
[TBL] [Abstract][Full Text] [Related]
36. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
Morissette SL; Almarsson O; Peterson ML; Remenar JF; Read MJ; Lemmo AV; Ellis S; Cima MJ; Gardner CR
Adv Drug Deliv Rev; 2004 Feb; 56(3):275-300. PubMed ID: 14962582
[TBL] [Abstract][Full Text] [Related]
37. Development and validation of an LC-UV method for the quantification and purity determination of the novel anticancer agent C1311 and its pharmaceutical dosage form.
den Brok MW; Nuijen B; Hillebrand MJ; Grieshaber CK; Harvey MD; Beijnen JH
J Pharm Biomed Anal; 2005 Sep; 39(1-2):46-53. PubMed ID: 15899571
[TBL] [Abstract][Full Text] [Related]
38. Stability studies of ionised and non-ionised 3,4-diaminopyridine: hypothesis of degradation pathways and chemical structure of degradation products.
Raust JA; Goulay-Dufaÿ S; Le Hoang MD; Pradeau D; Guyon F; Do B
J Pharm Biomed Anal; 2007 Jan; 43(1):83-8. PubMed ID: 16844337
[TBL] [Abstract][Full Text] [Related]
39. A novel approach for analyzing glass-transition temperature vs. composition patterns: application to pharmaceutical compound+polymer systems.
Kalogeras IM
Eur J Pharm Sci; 2011 Apr; 42(5):470-83. PubMed ID: 21324354
[TBL] [Abstract][Full Text] [Related]
40. The Effect of In-Situ-Generated Moisture on Disproportionation of Pharmaceutical Salt.
Weldeab AO; McElderry JD; Lin Y
Mol Pharm; 2023 Jan; 20(1):561-571. PubMed ID: 36524757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
